Developing a test to detect harmful antibodies related to Heparin-induced Thrombocytopenia
An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-induced Thrombocytopenia
['FUNDING_SBIR_2'] · RETHAM TECHNOLOGIES, INC. · NIH-11055939
This study is working on a new, more accurate test to help doctors find out if patients have Heparin-induced Thrombocytopenia (HIT), a serious condition that can happen when they receive heparin treatment, so that patients can get the right care without the confusion of false-positive results from current tests.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RETHAM TECHNOLOGIES, INC. (nih funded) |
| Locations | 1 site (Wauwatosa, UNITED STATES) |
| Trial ID | NIH-11055939 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a highly accurate diagnostic test to identify pathogenic antibodies associated with Heparin-induced Thrombocytopenia (HIT), a serious condition that can occur in patients receiving heparin treatment. The approach utilizes Platelet Factor 4 (PF4)-treated platelets to improve the sensitivity and specificity of the detection process. By providing a more reliable diagnosis, this test aims to reduce the number of patients who are incorrectly treated due to false-positive results from existing tests. The goal is to streamline the diagnostic process and enhance patient outcomes in those suspected of having HIT.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who are receiving heparin treatment and are suspected of having Heparin-induced Thrombocytopenia.
Not a fit: Patients who are not receiving heparin or those who do not have any risk factors for HIT may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses of HIT, reducing unnecessary treatments and improving patient safety.
How similar studies have performed: Previous research has shown that functional assays can improve the accuracy of HIT diagnosis, indicating that this approach has potential for success.
Where this research is happening
Wauwatosa, UNITED STATES
- RETHAM TECHNOLOGIES, INC. — Wauwatosa, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JONES, CURTIS — RETHAM TECHNOLOGIES, INC.
- Study coordinator: JONES, CURTIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.